Logo

Guava CEO Rajen Dalal Resigns; Chairman John Walker Takes Over

Feb 01, 2005

NEW YORK, Feb. 1 (GenomeWeb News) - Guava Technologies President and CEO Rajen Dalal has resigned, the Hayward, Calif.-based company said today. John Walker, the chairman of Guava's board of directors, has taken over the company as interim CEO.

 

No information about the reason for Dalal's resignation was immediately available from the company.

 

In addition to his involvement with Guava, Walkeris an investment advisor to MDS Capital and a vice chairman for biotechnology company Renovis. He is also a director of Discovery Partners International, Geron, and KAI Pharmaceuticals.

 

In the past, Walkerwas CEO of KAI Pharmaceuticals, Bayhill Therapeutics, Centaur Pharmaceuticals, and Axys Pharmaceuticals.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.